Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Wang, Yan; Chen, Jianhua; Wu, Shengqi; Hu, Chenping; Li, Xiaoling; Wang, Yuqin; Yang, Yicheng; Rajan, Narayan; Chen, Yun; Chen, Yi; Luo, Zhuanzhuan; Chen, Wendong

doi:10.1186/1471-2407-14-940

Table 2 Head-to-head comparisons of treatment pattern and tumor response between the propensity score matched treatment groups

From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Comparison	Platinum/Pemetrexed vs. Platinum/Docetaxel								Platinum/Pemetrexed vs. Platinum/Paclitaxel								Platinum/Pemetrexed vs. Platinum/Gemcitabine								Platinum/Pemetrexed vs. Platinum/Vinorelbine
Matched pairs	95						RR	P value*	118						RR	P value*	199						RR	P value*	72						RR	P value*
Measured outcomes	N	Mean/%	STDEV	N	Mean/%	STDEV			N	Mean/%	STDEV	N	Mean/%	STDEV			N	Mean/%	STDEV	N	Mean/%	STDEV			N	Mean/%	STDEV	N	Mean/%	STDEV
Treatment pattern
Completed treatment cycles	95	3.4	1.7		95	2.9	1.7	*0.028*	118	3.6	1.7	118	2.9	1.6		*0.006*	199	3.6	1.7	199	2.7	1.5		*<0.001*	72	3.3	1.7	72	2.5	1.3		*0.003*
Length of hospital stay per cycle (days)	95	10.1	6.7	95	11.5	8.2		0.191	118	10.4	6.1	118	13.5	11.7		*0.011*	199	10.9	6.0	199	15.0	7.0		*<0.001*	72	13.1	7.2	72	16.9	8.5		*0.001*
Tumor response based on RECIST (%)
PR	13	13.7%		13	13.7%		1.000	1.000	22	18.6%		6	5.1%		3.647	*0.002*	36	18.1%		18	9.1%		1.989	*0.007*	16	22.2%		9	12.5%		1.776	0.108
SD	44	46.3%		29	30.5%		1.518	*0.025*	45	38.1%		32	27.1%		1.406	0.074	72	36.2%		52	26.1%		1.387	*0.043*	28	38.9%		18	25.0%		1.556	0.077
PD	9	9.5%		13	13.7%		0.693	0.371	11	9.3%		21	17.8%		0.522	0.059	24	12.1%		23	11.6%		1.043	0.879	7	9.7%		12	16.7%		0.581	0.197
Unknown	29	30.5%		40	42.1%		0.724	0.101	40	33.9%		59	50.0%		0.678	*0.020*	67	33.7%		106	53.3%		0.632	*<0.001*	21	29.2%		33	45.8%		0.638	*0.029*
Other tumor response outcomes (%)
Early treatment discontinuation	45	47.4%		62	65.3%		0.726	*0.007*	52	44.1%		71	60.2%		0.732	*0.022*	91	45.7%		135	67.8%		0.674	*<0.001*	38	52.8%		55	76.4%		0.691	*0.007*
Tumor control	57	60.0%		42	44.2%		1.357	*0.029*	67	56.8%		38	32.2%		1.764	*<0.001*	108	54.3%		70	35.2%		1.543	*<0.001*	44	61.1%		20	27.5%		2.222	*0.005*
Treatment failure	38	40.0%		53	55.8%		0.717	*0.029*	51	43.2%		80	67.8%		0.637	*<0.001*	91	45.7%		129	64.8%		0.705	*<0.001*	28	38.9%		45	72.5%	0.537		*0.005*

STDEV, standard deviation; RR, rate ratio; RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, stable disease; PD, progressive disease. *: P values less than 0.05 were in bold to indicate significant differences.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us